You are currently viewing a new version of our website. To view the old version click .
Viruses
  • Correction
  • Open Access

4 March 2024

Correction: Cook et al. An Optimized Bioassay for Screening Combined Anticoronaviral Compounds for Efficacy against Feline Infectious Peritonitis Virus with Pharmacokinetic Analyses of GS-441524, Remdesivir, and Molnupiravir in Cats. Viruses 2022, 14, 2429

,
,
,
,
,
,
,
,
and
1
Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University of California-Davis, Davis, CA 95616, USA
2
Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California-Davis, Davis, CA 95616, USA
3
Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA
4
Office of Research, Campus Veterinary Services, University of California-Davis, Davis, CA 95616, USA
This article belongs to the Special Issue Coronaviruses across Species, a Comparative Approach

Error in Table

In the original publication [1], incorrect numerical data were entered into the last three numbers in the AUC column of Table 5 and this mistake was not recognized by our review team. This error was identified by Sally Coggins who brought it to our attention. Corrected Table 5 appears below.
Table 5. Pharmacokinetic parameters for GS-441524 after a single IV dose of RDV (7 mg/kg) in 3 cats.
Table 5. Pharmacokinetic parameters for GS-441524 after a single IV dose of RDV (7 mg/kg) in 3 cats.
Cat IDCmax
(ng/mL; μM)
Tmax
(h)
T1/2
(h)
AUC
(h*ng/mL)
20-0451730 (5.94)0.55.314,271
21-0011960 (6.73)15.715,291
21-0042320 (7.97)14.59924
Mean2003 (6.88)0.835.213,162
SD297 (1.0)0.290.62850

Text Correction

With regard to the correction of Table 5, a correction has been made to Section 3.4, Paragraph 3.
“Finally, in the IV RDV cohort, GS-441524 exhibited an average plasma Cmax of 2003 ng/mL (6.9 μM) at a corresponding Tmax of 0.83 h and an average AUC0-24 value of 13,162 h*ng/mL (45 μM*h; average C24 = 64 ± 32 ng/mL, 0.22 ± 0.11 μM) (Table 5).”
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Cook, S.; Wittenburg, L.; Yan, V.C.; Theil, J.H.; Castillo, D.; Reagan, K.; Williams, S.; Pham, C.-D.; Li, C.; Muller, F.L.; et al. An Optimized Bioassay for Screening Combined Anticoronaviral Compounds for Efficacy against Feline Infectious Peritonitis Virus with Pharmacokinetic Analyses of GS-441524, Remdesivir, and Molnupiravir in Cats. Viruses 2022, 14, 2429. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.